ALK and lung carcinoma: Non‐small‐cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer patients, with anaplastic lymphoma kinase (ALK) rearrangements occurring in approximately 3%–7% of NSCLC patients [2].